DexCom (DXCM) faces GLP-1 disruption as it targets non-insulin Type 2 CGM growth. Read here for a detailed invesment analysis ...

Celebrity ambassadors in pharma and medtech herald a new dawn of direct-to-consumer advertising.

The wearable patch market is estimated at roughly $ 13- $15 billion in 2026 and is expected to reach the low-twenties of ...

Samsung Galaxy Watch blood sugar tracking is still a rumor, not reality. Here’s the timeline, research, current options, and ...

On June 8, at the American Diabetes Association meeting, Adaptyx Biosciences put up data the field has chased for ten years ...

Snap’s $2,195 Specs bring full AR displays, AI assistance, and privacy questions to a wearables market led by Meta smart glasses.

JPMorgan upgrades IBM to overweight from neutral JPMorgan said it sees "software acceleration." "We are upgrading to ...

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current ...

Returns on pharmaceutical R&D among the world’s top 20 drugmakers rose to 7% in 2025, driven largely by GLP-1-related assets. Obesity treatments now account for roughly 25% of projected late-stage ...

Insulet (PODD) stock and DexCom (DXCM) receive new Buy ratings from Deutsche Bank while Tandem Diabetes Care (TNDM) stock ...

June 6 (Reuters) - Medical device maker Dexcom (DXCM.O), opens new tab said the use of its continuous glucose monitor, G7, led to improved blood sugar control in patients with type 2 diabetes not ...

Dexcom is transforming its Stelo CGM into a whole-family wellness device, securing FDA clearance for pediatric use and debuting new AI tools.